What were Sanofi's first-quarter net sales and growth rate, and what drug primarily drove this performance?

Sanofi reported first-quarter net sales of 10.5 billion euros, representing a 6.2% increase, largely driven by strong demand for its anti-inflammatory drug Dupixent.

Despite upbeat sales, what key challenges is Sanofi currently facing according to the news?

Sanofi is facing a period of transition with a new CEO, mounting pressure from a series of research setbacks, looming competition for its blockbuster drug Dupixent, and a 'challenging environment' for its vaccine unit.

Sanofi posts upbeat sales as R&D pressure builds

Apr 23, 2026

Sanofi reported a 6.2% increase in Q1 net sales to 10.5 billion euros, driven by Dupixent demand, despite facing R&D setbacks and leadership transitions.

BioPharma Dive

2026-04-09

Marathon and Valero Have Surged: Is the Party Over or Just Getting Started?

2026-04-11

Coerente Capital Management Boosts EOG Resources Stake

2026-04-18

Rockwell Automation Adds AMETEK CEO to Board of Directors

2026-04-23

Sanofi posts upbeat sales as R&D pressure builds

2026-04-29

Archer Daniels Midland stock hits 52-week high at 74.21 USD